Healthcare startup Heidi landed $340 million to fuel its push beyond clinical documentation into AI-powered workflow automation and agentic capabilities for clinicians.
The company, which first launched in Australia, initially started as an ambient AI medical scribe and then expanded into point-of-care clinical guidelines with Heidi Evidence and AI hardware (Remote) for clinical work as well as a voice-to-text feature, called Dictate.
Heidi says it now supports around 2.8 million patient interactions each week in 110 languages from 190 countries.
Blackbird led Heidi's $100 million series C funding, which was also backed by existing investors including Phoenix Court, Point72 Private Investments and Headline. The round values Heidi at $900 million, the company said.
Alongside the equity round, Heidi also secured a $240 million growth investment led by General Catalyst’s Customer Value Fund, providing large-scale go-to-market investment capacity to support Heidi's rapid growth and scale, executives said.
Heidi will use the funding to expand its capabilities beyond the visit, moving from documentation into supervised action and giving clinicians more time back for patients.
The investment supports Heidi's next phase of growth as it deepens adoption within health systems and brings agentic capabilities to support the clinical work around patient visits.
"From the day I started Heidi, the ambition was always bigger than writing doctor’s notes. I imagined that AI would sit alongside clinicians and complete real work under their supervision," Thomas Kelly, co-founder and CEO of Heidi, said in a statement. "That’s the shift we’re now making: from documenting care to helping clinicians act on it. This round is about getting an AI Care Partner to every doctor in the world, and putting clinicians back at the center of care with their patients."
In the past two years, Heidi's "AI care partner" has supported more than 175 million patient visits, up from 73 million at its series B fundraise, and over 67 million clinical hours, more than tripling since September 2025. Executives said annual recurring revenue grew from $1 million to $50 million in just two years.
The company has grown its reach with health systems. In the U.S., Boston-based Beth Israel Lahey Health expanded Heidi's AI scribe technology to all of its physicians across the health system. In the UK, Heidi was selected as sole supplier for the NHS England Midlands, the largest clinical AI procurement in NHS history.
In Australia, deployments include The Royal Children's Hospital Melbourne, Children's Health Queensland Hospital and Health Service, and Metro South Health. In New Zealand, Heidi was deployed across every emergency department in the country.
Earlier this year, the company launched Evidence, a clinical decision support tool that surfaces relevant research during the encounter. Heidi Evidence has answered over 10 million queries since launching in March 2026, according to the company. Heidi also shipped its first wearable device, Remote, built to work across settings, from surgery to community clinics, and Dictate, a voice-to-text feature.
Kelly told Fierce Healthcare in March that Heidi was evolving from an AI scribe to an AI care partner to connect clinical documentation and real-time clinical reasoning. The aim is to expand clinical capacity by automating administrative work, he said.
“We see a transition from these scribes becoming more of an AI partner for many parts of the practice. The documentation is really valuable, but doctors make lots of clinical decisions, and it’s also about addressing capacity. The mission for the company is to try to increase healthcare capacity. The supply-demand mismatch is so severe that, basically, if we're succeeding at Heidi, we should be trying to improve that curve in some way,” Kelly told Fierce Healthcare in an interview in February about the launch of Heidi's Evidence feature. “To do that, you have to make the existing system more productive, but that only gets you so far. I think we see ourselves as ultimately having to get closer and closer to delivering care.”
In March, the company unveiled a partnership with R1 RCM to integrate the company's clinical documentation tech directly into R1’s revenue operating system.
"Our Customer Value Fund (CVF) exists to help companies with excellent unit economics double down on their growth engine, while using their own balance sheet for product and engineering investments. Heidi has shown it can win trust inside the world's most complex health systems. We're thrilled to partner on Heidi's next phase of growth as they move from easing documentation to taking on more of the clinical work day," said Pranav Singhvi, co-founder and partner at CVF, General Catalyst, in a statement.